Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition

Molecular Pharmacology

Volumn 80, Issue 5, 2011, Pages 859-869

  Wu, Hong Min ^a   Yang, Yoon Mee ^a   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIVER X RECEPTOR ALPHA; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PERTUSSIS TOXIN; RIMONABANT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE INDUCTION; HUMAN; HUMAN CELL; LIPOGENESIS; LIVER CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TRANSACTIVATION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BASE SEQUENCE; CELL LINE; DNA PRIMERS; ENERGY METABOLISM; ENZYME ACTIVATION; GTP-BINDING PROTEINS; HEPATOCYTES; HUMANS; MICE; PIPERIDINES; PROTEIN-SERINE-THREONINE KINASES; PYRAZOLES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CANNABINOID;

EID: 80054789655     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.072769     Document Type: Article

References (48)

1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM, Third National Health and Nutrition Examination Survey (NHANES III), and National Cholesterol Education Program (NCEP) (2003) NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-1214. (Pubitemid 36523358)
2. Bae EJ, Yang YM, Kim JW, and Kim SG (2007) Identification of a novel class of dithiolethiones that prevent hepatic insulin resistance via the adenosine monophosphate- activated protein kinase-p70 ribosomal S6 kinase-1 pathway. Hepatology 46:730-739.
3. Bayewitch M, Avidor-Reiss T, Levy R, Barg J, Mechoulam R, and Vogel Z (1995) The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett 375:143-147.
4. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC, and Alessi DR (2003) MO25α/β interact with STRADα/β enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 22:5102-5114. (Pubitemid 37222030)
5. Collins SP, Reoma JL, Gamm DM, and Uhler MD (2000) LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem J 345:673-680. (Pubitemid 30099098)
6. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, and Eckel RH (2008) The metabolic syndrome. Endocr Rev 29:777-822.
7. Cummings DE, Brandon EP, Planas JV, Motamed K, Idzerda RL, and McKnight GS (1996) Genetically lean mice result from targeted disruption of the RII β subunit of protein kinase A. Nature 382:622-626. (Pubitemid 26268953)
8. De Gottardi A, Spahr L, Ravier-Dall'Antonia F, and Hadengue A (2010) Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes. Liver Int 30:1482-1489.
9. Després JP, Golay A, Sjöström L, and Rimonabant in Obesity-Lipids Study Group (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134. (Pubitemid 41653104)
10. Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, Vaahtomeri K, Auchli Y, Rechsteiner H, Brunisholz RA, et al. (2010) PKA phosphorylates and inactivates AMPKα to promote efficient lipolysis. EMBO J 29:469-481.
11. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D'Esposito V, Beguinot F, Formisano P, and Bifulco M (2008) The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 74:1678-1686.
12. 2 receptors. Mol Pharmacol 56:1362-1369.
13. Han CY, Ki SH, Kim YW, Noh K, Lee da Y, Kang B, Ryu JH, Jeon R, Kim EH, Hwang SJ, et al. (2011) Ajoene, a stable garlic by-product, inhibits high fat diet-induced hepatic steatosis and oxidative injury through LKB1-dependent AMPK activation. Antioxid Redox Signal 14:187-202.
14. Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, MäkeläTP, Alessi DR, and Hardie DG (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2:28.
15. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, and Hardie DG (2005) Calmodulin-dependent protein kinase kinase-β is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab 2:9-19. (Pubitemid 43239821)
16. Hollander PA, Amod A, Litwak LE, Chaudhari U, and ARPEGGIO Study Group (2010) Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. Diabetes Care 33:605-607.
17. Howlett AC, Qualy JM, and Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307-313. (Pubitemid 16137598)
18. Huang NL, Juang JM, Wang YH, Hsueh CH, Liang YJ, Lin JL, Tsai CT, and Lai LP (2010) Rimonabant inhibits TNF-α-induced endothelial IL-6 secretion via CB1 receptor and cAMP-dependent protein kinase pathway. Acta Pharmacol Sin 31:1447-1453.
19. Hwahng SH, Ki SH, Bae EJ, Kim HE, and Kim SG (2009) Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-α-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology 49:1913-1925.
20. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Bátkai S, Mukhopadhyay P, Horiguchi N, Harvey-White J, Marsicano G, Lutz B, et al. (2008) Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 7:227-235. (Pubitemid 351285525)
21. Jourdan T, Djaouti L, Demizieux L, Gresti J, Vergès B, and Degrace P (2010) CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 59:926-934.
22. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, Mitchell SE, Williams LM, Hawley SA, Hardie DG, Grossman AB, et al. (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280:25196-25201. (Pubitemid 40934612)
23. Kotronen A and Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27-38.
24. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, and Tontonoz P (2001) Autoregulation of the human liver X receptor α promoter. Mol Cell Biol 21:7558-7568. (Pubitemid 32988767)
25. Lan F, Cacicedo JM, Ruderman N, and Ido Y (2008) SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283:27628-27635.
26. Liu YL, Connoley IP, Wilson CA, and Stock MJ (2005) Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/Lepob mice. Int J Obes (Lond) 29:183-187. (Pubitemid 40188413)
27. Lu M and Shyy JY (2006) Sterol regulatory element-binding protein 1 is negatively modulated by PKA phosphorylation. Am J Physiol Cell Physiol 290:C1477-C1486. (Pubitemid 43830787)
28. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, and Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14:72-81.
29. McKnight GS, Cummings DE, Amieux PS, Sikorski MA, Brandon EP, Planas JV, Motamed K, and Idzerda RL (1998) Cyclic AMP, PKA, and the physiological regulation of adiposity. Recent Prog Horm Res 53:139-159; discussion 160-161.
30. Mitro N, Vargas L, Romeo R, Koder A, and Saez E (2007) T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 581:1721-1726. (Pubitemid 46602262)
31. Motoshima H, Goldstein BJ, Igata M, and Araki E (2006) AMPK and cell proliferation - AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 574:63-71. (Pubitemid 43905797)
32. Nathan PJ, O'Neill BV, Napolitano A, and Bullmore ET (2010) Neuropsychiatric adverse effects of centrally acting antiobesity drugs. CNS Neurosci Ther doi: 10.1111/j.1755-5949.2010.00172.x.
33. Neves SR, Ram PT, and Iyengar R (2002) G protein pathways. Science 296:1636-1639. (Pubitemid 34579147)
34. Ntambi JM (1999) Regulation of stearoyl-CoA desaturase by polyunsaturated fatty acids and cholesterol. J Lipid Res 40:1549-1558.
35. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Bátkai S, Harvey-White J, Mackie K, Offertáler L, Wang L, et al. (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305. (Pubitemid 40629049)
36. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, and Mangelsdorf DJ (2000) Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRαand LXRβ. Genes Dev 14:2819-2830.
37. Sakoda H, Ogihara T, Anai M, Fujishiro M, Ono H, Onishi Y, Katagiri H, Abe M, Fukushima Y, Shojima N, et al. (2002) Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes. Am J Physiol Endocrinol Metab 282:E1239-E1244. (Pubitemid 34654692)
38. 433, is essential for LKB1 to suppress cell growth. J Biol Chem 276:19469-19482.
39. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, and RIO-Diabetes Study Group (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368:1660-1672. (Pubitemid 46048528)
40. Schreyer SA, Cummings DE, McKnight GS, and LeBoeuf RC (2001) Mutation of the RIIβ subunit of protein kinase A prevents diet-induced insulin resistance and dyslipidemia in mice. Diabetes 50:2555-2562. (Pubitemid 33642774)
41. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L, Schwendner S, Wang S, Thoolen M, Mangelsdorf DJ, et al. (2000) Role of LXRs in control of lipogenesis. Genes Dev 14:2831-2838.
42. Shin SM, Cho IJ, and Kim SG (2009) Resveratrol protects mitochondria against oxidative stress through AMP-activated protein kinase-mediated glycogen synthase kinase-3 inhibition downstream of poly(ADP-ribose)polymerase-LKB1 pathway. Mol Pharmacol 76:884-895.
43. Stoeckman AK and Towle HC (2002) The role of SREBP-1c in nutritional regulation of lipogenic enzyme gene expression. J Biol Chem 277:27029-27035. (Pubitemid 34951715)
44. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rössner S, and RIO-Europe Study Group (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397. (Pubitemid 40523733)
45. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, et al. (2009) Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 284:1803-1812.
46. Yamamoto T, Shimano H, Inoue N, Nakagawa Y, Matsuzaka T, Takahashi A, Yahagi N, Sone H, Suzuki H, Toyoshima H, et al. (2007) Protein kinase A suppresses sterol regulatory element-binding protein-1C expression via phosphorylation of liver X receptor in the liver. J Biol Chem 282:11687-11695. (Pubitemid 47100691)
47. Yan ZC, Liu DY, Zhang LL, Shen CY, Ma QL, Cao TB, Wang LJ, Nie H, Zidek W, Tepel M, et al. (2007) Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-delta. Biochem Biophys Res Commun 354:427-433. (Pubitemid 46172454)
48. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174. (Pubitemid 32995375)